SPEXIS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0542 CHF | -15.05% |
|
-8.14% | +32.20% |
| 01/05 | SIX Swiss Exchange Approves Delay in Spexis' FY23 Annual Report Publication | MT |
| 17/04 | Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| SPEXIS AG | Biopharmaceuticals | -15.05% | -8.14% | +32.20% | -86.24% | - | 4.05M |  |  | |
Technical Rankings Surperformance
- Stock Market
- Equities
- POLN Stock
- Charts Spexis AG
- Comparison Chart
